Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tr… Read more
Sansure Biotech Inc (688289) - Total Liabilities
Latest total liabilities as of September 2025: CN¥2.24 Billion CNY
Based on the latest financial reports, Sansure Biotech Inc (688289) has total liabilities worth CN¥2.24 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sansure Biotech Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Sansure Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sansure Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Sansure Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
San Miguel AG
BA:SAMI
|
Argentina | AR$515.35 Billion |
|
Shanghai Smith Adhesive New
SHG:603683
|
China | CN¥1.38 Billion |
|
Northern Dynasty Minerals Ltd
NYSE MKT:NAK
|
USA | $66.90 Million |
|
OceanaGold Corporation
PINK:OCANF
|
USA | $1.06 Billion |
|
Jiangsu Gian Technology Co Ltd
SHE:300709
|
China | CN¥1.83 Billion |
|
Shenzhen Injoinic Technology Co. Ltd. A
SHG:688209
|
China | CN¥133.27 Million |
|
MLOptic Corp. A
SHG:688502
|
China | CN¥352.18 Million |
|
Shandong Dawn Polymer Co Ltd
SHE:002838
|
China | CN¥3.17 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Sansure Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sansure Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sansure Biotech Inc (2017–2024)
The table below shows the annual total liabilities of Sansure Biotech Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.26 Billion | +22.22% |
| 2023-12-31 | CN¥1.03 Billion | -38.03% |
| 2022-12-31 | CN¥1.66 Billion | +134.26% |
| 2021-12-31 | CN¥709.03 Million | +0.01% |
| 2020-12-31 | CN¥708.95 Million | +734.17% |
| 2019-12-31 | CN¥84.99 Million | -45.43% |
| 2018-12-31 | CN¥155.76 Million | -16.54% |
| 2017-12-31 | CN¥186.62 Million | -- |